title: Effects of captopril and enalapril on zinc metabolism in hypertensive patients.
abstract: OBJECTIVE
  To investigate the effect of chronic captopril and enalapril treatment on zinc metabolism in hypertensive patients by assessing zinc levels in serum, urine and monocytes.
  
  
  METHODS
  Patients with newly diagnosed essential hypertension were randomly divided into two treatment groups: those treated with captopril only (n = 16) and those treated with enalapril only (n = 18). Ten healthy subjects served as controls. Prior to the start of treatment and again 6 months later, zinc was assessed in the serum, in urine collected over 24 hours, and in peripheral blood monocytes.
  
  
  RESULTS
  Significant enhancement of 24-hour urinary zinc excretion (micrograms/24 hour) after 6 months of treatment was observed only in the captopril-treated group (p < 0.01). However, intramonocytic zinc levels decreased significantly in both of the treated groups over the same period (p < 0.01 and P < 0.04 in the captopril- and enalapril-treated groups, respectively).
  
  
  CONCLUSIONS
  Treatment of hypertensive patients with captopril or enalapril may result in zinc deficiency.
authors.affiliation: Department of Internal Medicine A, Assaf Harofeh Medical Center, Zerifin, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Golik
authors.forename: R
authors.initials: R
authors.lastname: Zaidenstein
authors.forename: V
authors.initials: V
authors.lastname: Dishi
authors.forename: A
authors.initials: A
authors.lastname: Blatt
authors.forename: N
authors.initials: N
authors.lastname: Cohen
authors.forename: G
authors.initials: G
authors.lastname: Cotter
authors.forename: S
authors.initials: S
authors.lastname: Berman
authors.forename: J
authors.initials: J
authors.lastname: Weissgarten
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D004656:Enalapril / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D009000:Monocytes / Q000378:metabolism*; D011446:Prospective Studies; D015032:Zinc / Q000097:blood / Q000378:metabolism* / Q000652:urine
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004656:Enalapril; D002216:Captopril; D015032:Zinc